Pathology Visions 2024—Decision Digital
October 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla. The theme for Pathology Visions 2024 is “Decision Digital.”
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Cepheid Xpert HCV gets FDA authorization, waiver
September 2024—Cepheid has received FDA de novo marketing authorization and CLIA waiver approval for its Xpert HCV, the first point-of-care hepatitis C RNA test. The test can accurately detect active HCV infection from individuals at risk and/or with signs and symptoms of HCV infection with or without antibodies to HCV from a capillary blood sample.
Agilent expands solutions to help labs manage environmental footprint
September 2024—Agilent Technologies released in June its 2023 environmental, social, and governance report, showcasing sustainable solutions that enable labs worldwide to reduce consumption of nonrenewable resources and minimize waste.
Qiagen, Myriad to develop HRD test
September 2024—Qiagen and Myriad Genetics announced they will develop a globally distributable kit-based test for analyzing homologous recombination deficiency status. This next-generation sequencing test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer, and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the master collaboration agreement that the companies announced in October 2023.
Bio-Rad launches Specialty Immunoassay Plus controls
September 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures. The product is available in barcoded, load-and-go InteliQ and standard vial Liquichek configurations and features clinically relevant analytes such as procalcitonin, interleukin-6, active vitamin B12, anti-TSH receptor, thyroid stimulating immunoglobulins, fructosamine, and others. It also contains optimized vitamin D ranges to support Vitamin D Standardization Program–compliant assays and improved intact parathyroid hormone open-vial stability to minimize QC waste. With the Unity data management software, laboratories can compare results across a large peer group of reporting labs.
Cobas Liat SARS-CoV-2, flu A/B, RSV test gets EUA
September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.
Siemens offers NT‑proBNPII assay on Atellica Solution
September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.
Spotfire R/ST Panel Mini gets special clearance, CLIA waiver
September 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
Qiagen launches digital PCR assays for microbial applications
September 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity. The assays are available on Qiagen’s research platform GeneGlobe and are designed to target a wide range of pathogens, including dengue virus serotypes one to four, mpox clades one and two, and chikungunya, as well as malaria and various sexually transmitted infections and urinary tract infections. The addition of these assays brings the company’s total microbial dPCR assay portfolio to more than 680 targets.
BD, Quest to develop companion diagnostics
September 2024—BD and Quest Diagnostics announced a worldwide collaboration agreement to develop, manufacture, and commercialize flow-cytometry–based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.